Kadderum

Eltrombopag, the active ingredient in Kadderum, is a thrombopoietin receptor agonist presented as an oral tablet for oral use. It treats chronic immune thrombocytopenia and severe aplastic anemia in appropriate patients.

GNH USA supplies Kadderum as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Eltrombopag acts on the thrombopoietin pathway to increase platelet production in several hematologic conditions.

- Chronic immune thrombocytopenia (ITP): raises platelet counts in patients with persistent low platelets. - Severe aplastic anemia: supports platelet generation as part of broader marrow recovery. - Hepatitis C‑related thrombocytopenia: improves platelet levels to enable antiviral therapy.

Eltrombopag may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools that may be transient. - Headache: mild tension‑type pain. - Fatigue: general tiredness. - Elevated liver enzymes: mild transaminase rise. - Dyspepsia: indigestion or upper abdominal discomfort.

Serious or Rare Side Effects: - Thromboembolic events: clot formation in veins or arteries. - Severe liver injury: marked elevation of hepatic enzymes or hepatitis. - Worsening aplastic anemia: further suppression of bone‑marrow function. - Severe neutropenia: marked reduction in neutrophil count. - Cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Retinal pigment changes: visual disturbances requiring ophthalmic review.

Before initiating therapy, clinicians should evaluate baseline parameters and monitor patients regularly.

- Liver function monitoring: check transaminases before and during treatment. - Hematologic surveillance: perform complete blood counts periodically. - Avoid in active thrombosis: contraindicated in patients with recent clotting events. - Pregnancy caution: safety not established; weigh benefits against risks. - Drug interaction vigilance: review concomitant CYP3A4 inducers or inhibitors. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Eltrombopag can interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce exposure. - Antacids containing polyvalent cations (e.g., calcium, magnesium): impair oral absorption. - Warfarin: may increase INR and bleeding risk.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., ketoconazole, fluconazole): increase plasma levels. - Oral contraceptives: potential reduction in contraceptive effectiveness. - Other myelosuppressive agents: additive bone‑marrow suppression. - Statins metabolized by CYP3A4: monitor for increased statin exposure.